RECOMBINATION THERAPEUTICS LLC

Philadelphia, PA · Biotech · Private

Small-molecule DNA polymerase theta (Polθ) inhibitor for treating BRCA-deficient acute myeloid leukemia

Claim this profile

Follows are private to you and power your alerts

Updated · recombinationtx.com

Sector
Biotech
Headquarters
Philadelphia, PA
Total capital
$2.2M
Federal grants
$2.2M
6 awards · 2020–2021
Rank in peer group#279 of 326
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
3 pending

Capital timeline

20202021FEDERAL ↑EQUITY ↓Cumulative $2.2M$299K$299K$400K$400K$386K$386K
20202021FEDERAL ↑EQUITY ↓Cumulative $2.2M$400K$400K$386K$386K

Latest events

  • Federal grantHealth and Human S · Phase I · Structure Based Design of Pol-theta inhibitors$386K
  • Federal grantHealth and Human S · Phase I · Structure Based Design of Pol-theta inhibitors$386K
  • Federal grantHealth and Human S · Phase I · Nucleotide inhibitors as precision medicine in breast cancer$400K
  • Federal grantHealth and Human S · Phase I · Nucleotide inhibitors as precision medicine in breast cancer$400K
  • Federal grantHealth and Human S · Phase I · Next-generation precision medicine for targeting recombination-deficient cancers$299K
  • Federal grantHealth and Human S · Phase I · Next-generation precision medicine for targeting recombination-deficient cancers$299K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 3
  • PendingDNA Polymerase Theta Inhibitors Containing Non-Saturated 5-Membered Heterocyclic Rings and Use ThereofUSPTOApplication 19144147
  • PendingDNA Polymerase Theta Inhibitors Containing Non-Saturated 5-Membered Heterocyclic Rings and Use ThereofUSPTOApplication 63477472
  • PendingPyrrolidine and Imidazolidine Based DNA Polymerase Theta Inhibitors and Use ThereofUSPTOApplication 19117545
  • ALEXANDER BIODISCOVERIES, LLCSimilar federal contract value in Biotech · null in contracts
  • Valora TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Exthymic CorpSimilar federal contract value in Biotech · null in contracts
  • CytokineticsSimilar federal contract value in Biotech · null in contracts
  • CurlBio LLCSimilar federal contract value in Biotech · null in contracts
  • DMK PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .